サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1322921

病理学向けAIの世界市場：コンポーネント別、ニューラルネットワーク別、用途別、エンドユーザー別、地域別 - 予測（～2028年）

AI in Pathology Market by Component (Software, Scanners), Neural Network (CNN, GAN, RNN), Application (Drug Discovery, Diagnosis, Prognosis, Workflow, Education), End User (Pharma, Biotech, Hospital Labs, Research), & Region - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 199 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
病理学向けAIの世界市場：コンポーネント別、ニューラルネットワーク別、用途別、エンドユーザー別、地域別 - 予測（～2028年）
出版日: 2023年07月14日
発行: MarketsandMarkets
ページ情報: 英文 199 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の病理学向けAI市場は、2023年に2,400万米ドル、2028年までに4,900万米ドルに達し、予測期間中にCAGRで15.6％の成長が予測されています。

"用途別では、創薬セグメントが予測期間中に最大のシェアを占める見込みです。"

2022年、創薬セグメントが市場で最大のシェアを占めました。このセグメントの大幅な成長は、ハイスループットスクリーニングとイメージング技術の進歩、違法薬物の毒物検査におけるAIの活用の増加、製薬とバイオテクノロジーの研究開発（R&D）への支出の増加、新治療法の開発を加速し、診断精度を向上させ、個別化医療へのアプローチを強化する病理学AIの能力など、さまざまな要因に起因します。これらの要因が、市場における創薬用途セグメントの大きなシェアにつながっています。

"製薬・バイオテクノロジー企業が2022年に市場でもっとも速く成長するエンドユーザーセグメントとなっています。"

製薬・バイオテクノロジー企業セグメントは予測期間中にもっとも高い成長率を示すと予測されています。このセグメントが大きなシェアを占め、急成長しているのは、創薬・医薬品開発プロセスの進歩に加え、薬物毒性試験向け病理学向けAIの活用が進んでいるためです。バイオテクノロジー企業は、バイオバンク、バイオ医薬品研究、分子アッセイ、個別化医療の開発など、さまざまな目的でAIベースのデジタル病理学を信頼しています。

"予測期間中、北米がもっとも高い成長率を示し、最大のシェアを占める見込みです。"

北米における市場成長は、いくつかの要因に起因しています。まず、同地域では病理学インフラの近代化のために多額の投資が行われており、これが市場成長の促進要因となっています。さらに、北米ではデジタル病理学ソリューションの採用が増加しており、市場全体の拡大に寄与しています。さらに、医療インフラの継続的な拡張と市場における先進AI技術の利用可能性の拡大が、この地域の成長をさらに後押ししています。技術、患者の安全性、品質向上への注目の高まりが、医療機器技術の進歩や政府の取り組みとともに、北米における病理学向けAIの採用を引き続き促進しています。

当レポートでは、世界の病理学向けAI市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主要考察

  • 病理学市場の概要
  • アジア太平洋：病理学向けAI市場：コンポーネント別、国別
  • 病理学向けAI市場の地理的スナップショット
  • 地域の構成：病理学向けAI市場
  • 病理学向けAI市場：先進国 VS. 途上国市場

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 産業考察

  • 産業動向
  • 病理学向けAIへの投資の増加
  • 技術分析
  • ポーターのファイブフォース分析
  • 規制分析
  • バリューチェーン分析
  • エコシステム
  • 特許分析
  • 主な会議とイベント（2023年～2024年）
  • ケーススタディ分析
  • 価格分析
  • 主なステークホルダーと購入基準

第7章 病理学向けAI市場：コンポーネント別

  • イントロダクション
  • ソフトウェア
  • スキャナー

第8章 病理学向けAI市場：ニューラルネットワーク別

  • イントロダクション
  • CNN
  • GAN
  • RNN
  • その他のニューラルネットワーク

第9章 病理学向けAI市場：用途別

  • イントロダクション
  • 創薬
  • 疾患の診断と予後
  • 臨床ワークフローの最適化
  • 訓練と教育

第10章 病理学向けAI市場：エンドユーザー別

  • イントロダクション
  • 製薬企業、バイオテクノロジー企業
  • 病院、リファレンスラボ
  • 学術・研究機関

第11章 病理学向けAI市場：地域別

  • イントロダクション
  • 北米
    • 北米：不況の影響
    • 米国
    • カナダ
  • 欧州
    • 欧州：不況の影響
    • 英国
    • ドイツ
    • フランス
    • その他の欧州
  • アジア太平洋
    • アジア太平洋：不況の影響
    • 中国
    • 日本
    • その他のアジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • イントロダクション
  • 主要企業の戦略/有力企業
  • 上位市場企業の収益分析（2022年）
  • 市場ランキング分析
  • 競合ベンチマーキング
  • 企業の評価マトリクス
  • スタートアップ/中小企業の評価マトリクス
  • 競合シナリオと動向

第13章 企業プロファイル

  • 主要企業
    • KONINKLIJKE PHILIPS N.V.
    • F. HOFFMANN-LA ROCHE LTD.
    • HOLOGIC, INC.
    • AKOYA BIOSCIENCES, INC.
    • AIFORIA TECHNOLOGIES PLC
    • INDICA LABS INC.
    • OPTRASCAN, INC.
    • IBEX MEDICAL ANALYTICS LTD.
    • MINDPEAK GMBH
    • TRIBUN HEALTH
    • TECHCYTE, INC.
    • DEEP BIO INC.
    • LUMEA INC.
    • VISIOPHARM
    • AETHER AI
    • AIOSYN
    • PAIGE AI, INC.
    • PROSCIA, INC.
    • PATHAI, INC.
    • TEMPUS LABS, INC.
  • その他の企業
    • KONFOONG BIOINFORMATION TECH CO., LTD.
    • DOMORE DIAGNOSTICS AS
    • VERILY LIFE SCIENCES, LLC
    • DEEPPATH
    • 4D PATH INC.

第14章 付録

目次
Product Code: HIT 8721

The global AI in pathology market is projected to reach USD 49 Million by 2028 from USD 24 Million in 2023, at a high CAGR of 15.6% during the forecast period. The AI in pathology market refers to the sector within the healthcare industry that encompasses the development, deployment, and utilization of artificial intelligence (AI) technologies specifically designed for pathology applications. AI models can analysed clinical data, genomic information, and pathology images to predict patient prognosis and disease progression. These models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. It involves the use of advanced computational algorithms, machine learning techniques, and computer vision methods to analyse pathology images, extract relevant information, and assist pathologists in diagnostic decision-making.

"The drug discovery segment accounted for the largest share during the forecast period, by application."

In 2022, the drug discovery segment held the largest share of the AI in pathology market. The significant growth in this segment can be attributed to various factors, including the advancements in high throughput screening and imaging technologies, the increasing utilization of AI in toxicology testing for illicit drugs, the rising expenditure on pharmaceutical and biotechnology research and development (R&D), and the ability of AI in pathology to accelerate the development of new therapeutics, improve diagnostic accuracy, and enhance approaches to personalized medicine. These factors contribute to the substantial share of the drug discovery application segment in the AI in pathology market.

"Pharmaceutical and biotechnology companies is the fastest growing end-user segment in the AI in pathology market in 2022."

The AI in pathology market is divided into different end-user segments, including pharmaceutical and biotechnology companies, hospitals and reference laboratories, and academic and research institutes. Among these, the pharmaceutical and biotechnology companies segment is projected to witness the highest growth rate during the forecast period. This segment's significant share and rapid growth can be attributed to the advancement of drug discovery and development processes, as well as the increasing utilization of AI in pathology for drug toxicology testing. Biotechnology companies rely on AI-based digital pathology for various purposes, including biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

"North America to witness the highest growth rate and accounted for largest share during the forecast period."

During the forecast period, the North America market is anticipated to exhibit the highest growth rate. The growth of the market in the North America region can be attributed to several factors. Firstly, there have been substantial investments to modernize pathology infrastructure in the region, which is driving market growth. Additionally, there is an increasing adoption of digital pathology solutions in North America, contributing to the overall market expansion. Moreover, the continuous expansion of the healthcare infrastructure and the growing availability of advanced AI technologies in the market are further boosting the growth in this region. The increasing focus on technology, patient safety, and quality improvement, combined with technological advancements in medical devices and government initiatives, continues to drive the adoption of AI in pathology market in North America.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Asia Pacific: 26%, Europe: 32%, Middle East & Africa: 5%, Latin America: 5%

Key Players in the AI in Pathology Market

The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).

Research Coverage:

The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on components, neural network, application, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of key drivers: (Increasing adoption of AI in pathology to enhance lab efficiency, growing digitization of pathology, augmenting telepathology with AI advancements, rise in cases of misdiagnoses, and technology advancements in deep learning enabling synergy with artificial intelligence (AI) in pathology space), restraints (high cost of digital pathology systems, lack of skilled AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing demand of personalized medicines, shortage of skilled pathologists), and challenges (lack of sufficient data to train the AI algorithms, data privacy concerns, lack of transparency and interoperability) influencing the growth of the AI in pathology market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, component, neural network, applications, end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKETS COVERED
    • 1.3.1 AI IN PATHOLOGY MARKET SEGMENTATION, BY REGION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS
    • 2.2.1 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 AI IN PATHOLOGY MARKET: RISK ASSESSMENT
  • 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 7 AI IN PATHOLOGY MARKET, BY COMPONENT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 8 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 AI IN PATHOLOGY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 AI IN PATHOLOGY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF AI IN PATHOLOGY MARKET

4 PREMIUM INSIGHTS

  • 4.1 AI IN PATHOLOGY MARKET OVERVIEW
    • FIGURE 12 GROWING DIGITIZATION OF PATHOLOGY TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT AND COUNTRY
    • FIGURE 13 SOFTWARE SEGMENT TO COMMAND LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • 4.3 GEOGRAPHIC SNAPSHOT OF AI IN PATHOLOGY MARKET
    • FIGURE 14 MARKET IN UK TO GROW AT HIGHEST CAGR
  • 4.4 REGIONAL MIX: AI IN PATHOLOGY MARKET
    • FIGURE 15 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 AI IN PATHOLOGY MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 16 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing number of partnerships and collaborations among players to develop and launch advanced AI in pathology solutions
      • 5.2.1.2 Growing digitalization of pathology
      • 5.2.1.3 Growing cases of misdiagnoses
      • 5.2.1.4 Augmenting telepathology with AI advancements
      • 5.2.1.5 Technological advancements in deep learning
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
      • 5.2.2.2 Shortage of skilled AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing demand for personalized medicine
    • TABLE 3 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES (2008-2020)
    • FIGURE 18 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
      • 5.2.3.2 Shortage of skilled pathologists
    • TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of sufficient data to train AI algorithms
      • 5.2.4.2 Data privacy concerns
    • FIGURE 19 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2021
      • 5.2.4.3 Lack of transparency and interoperability

6 INDUSTRY INSIGHTS

  • 6.1 INDUSTRY TRENDS
    • 6.1.1 IMPROVED QUALITY CONTROL WITH ARTIFICIAL INTELLIGENCE
    • 6.1.2 TRANSFORMATION IN STAINING TECHNIQUES
  • 6.2 INCREASING INVESTMENTS FOR AI IN PATHOLOGY
  • 6.3 TECHNOLOGY ANALYSIS
    • 6.3.1 MACHINE LEARNING (ML) AND DEEP LEARNING (DL)
    • 6.3.2 IMAGE ANALYSIS AND COMPUTER VISION
    • 6.3.3 NATURAL LANGUAGE PROCESSING (NLP)
    • 6.3.4 DATA INTEGRATION AND FUSION
    • 6.3.5 AUGMENTED PATHOLOGY AND DECISION SUPPORT SYSTEMS
    • 6.3.6 PREDICTIVE ANALYTICS AND PROGNOSTIC MODELS
    • 6.3.7 CLOUD COMPUTING AND BIG DATA INFRASTRUCTURE
  • 6.4 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 20 AI IN PATHOLOGY MARKET MARKED BY MODERATE TO HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS
    • TABLE 5 AI IN PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1 THREAT OF NEW ENTRANTS
    • 6.4.2 THREAT OF SUBSTITUTES
    • 6.4.3 BARGAINING POWER OF SUPPLIERS
    • 6.4.4 BARGAINING POWER OF BUYERS
    • 6.4.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.5 REGULATORY ANALYSIS
    • 6.5.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 6.5.2 REGULATORY ANALYSIS, BY REGION
      • 6.5.2.1 North America
        • 6.5.2.1.1 US
    • TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
        • 6.5.2.1.2 Canada
    • TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 6.5.2.2 Europe
    • TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 21 EUROPE: IVDR TIMELINE
      • 6.5.2.3 Asia Pacific
        • 6.5.2.3.1 Japan
    • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
        • 6.5.2.3.2 China
    • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • 6.6 VALUE-CHAIN ANALYSIS
    • FIGURE 22 VALUE-CHAIN ANALYSIS (2022)
  • 6.7 ECOSYSTEM
    • FIGURE 23 AI IN PATHOLOGY MARKET: ECOSYSTEM
  • 6.8 PATENT ANALYSIS
    • 6.8.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
    • FIGURE 24 NUMBER OF PATENTS PUBLISHED, JANUARY 2013 TO MAY 2023
    • 6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 25 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2013 TO MAY 2023)
    • FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN PATHOLOGY PATENTS (JANUARY 2013 TO MAY 2023)
  • 6.9 KEY CONFERENCES AND EVENTS, 2023-2024
    • TABLE 13 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS
  • 6.10 CASE STUDY ANALYSIS
    • 6.10.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
    • 6.10.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
  • 6.11 PRICING ANALYSIS
  • 6.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 6.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS
    • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%)
    • 6.12.2 BUYING CRITERIA
    • FIGURE 28 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
    • TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS

7 AI IN PATHOLOGY MARKET, BY COMPONENT

  • 7.1 INTRODUCTION
    • TABLE 16 AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
  • 7.2 SOFTWARE
    • 7.2.1 INTELLIGENT SOFTWARE HELPS REDUCE ERRORS CAUSED BY STANDARD PATHOLOGY APPROACHES
    • TABLE 17 AI IN PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SCANNERS
    • 7.3.1 USE OF AI IN SCANNERS ENHANCES SCANNING PROCESS AND IMPROVES IMAGE QUALITY
    • TABLE 18 AI IN PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

  • 8.1 INTRODUCTION
    • TABLE 19 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
  • 8.2 CONVOLUTIONAL NEURAL NETWORKS
    • 8.2.1 CONVOLUTIONAL NEURAL NETWORKS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
    • TABLE 20 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 GENERATIVE ADVERSARIAL NETWORKS
    • 8.3.1 GENERATED SYNTHETIC PATHOLOGY IMAGES CLOSELY RESEMBLE REAL PATHOLOGY
    • TABLE 21 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 RECURRENT NEURAL NETWORKS
    • 8.4.1 ABILITY OF RECURRENT NEURAL NETWORKS TO ANALYZE TIME-DEPENDENT PATTERNS TO PROPEL GROWTH
    • TABLE 22 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER NEURAL NETWORKS
    • TABLE 23 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY, 2021-2028 (USD MILLION)

9 AI IN PATHOLOGY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 24 AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 DRUG DISCOVERY
    • 9.2.1 DRUG DISCOVERY SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
    • TABLE 25 APPLICATIONS OF AI IN PATHOLOGY IN DRUG DISCOVERY
    • TABLE 26 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 DISEASE DIAGNOSIS AND PROGNOSIS
    • 9.3.1 GROWING USE OF AI AND ML FOR DIAGNOSTIC AND PROGNOSTIC PURPOSES TO PROPEL GROWTH
    • TABLE 27 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS AND PROGNOSIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 CLINICAL WORKFLOW OPTIMIZATION
    • 9.4.1 ADVANTAGES OF AI IN ENHANCING CLINICAL WORKFLOWS BY AUTOMATING REPETITIVE TASKS TO DRIVE GROWTH
    • TABLE 28 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 TRAINING AND EDUCATION
    • 9.5.1 APPLICATIONS IN IMPROVING TRAINING AND EDUCATION PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES TO DRIVE GROWTH
    • TABLE 29 AI IN PATHOLOGY MARKET FOR TRAINING AND EDUCATION, BY COUNTRY, 2021-2028 (USD MILLION)

10 AI IN PATHOLOGY MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 30 AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 10.2.1 RISING USE OF AI-BASED DIGITAL PATHOLOGY SOLUTIONS IN DRUG DEVELOPMENT TO DRIVE GROWTH
    • TABLE 31 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 HOSPITALS AND REFERENCE LABORATORIES
    • 10.3.1 RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH
    • TABLE 32 AI IN PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 ACADEMIC AND RESEARCH INSTITUTES
    • 10.4.1 INCREASING INVESTMENTS FOR RESEARCH IN DISEASE DIAGNOSIS TO SUPPORT GROWTH
    • TABLE 33 AI IN PATHOLOGY MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

11 AI IN PATHOLOGY MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 34 AI IN PATHOLOGY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
    • TABLE 35 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 US to dominate North American market during forecast period
    • TABLE 40 US: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 41 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 42 US: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 43 US: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing research in pathology to drive growth
    • TABLE 44 CANADA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 45 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 46 CANADA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 47 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 48 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 EUROPE: RECESSION IMPACT
    • 11.3.2 UK
      • 11.3.2.1 Adoption of AI in pathology for drug discovery to fuel growth
    • TABLE 53 UK: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 54 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 55 UK: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 56 UK: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 GERMANY
      • 11.3.3.1 Availability of funding for AI initiatives to boost growth
    • TABLE 57 GERMANY: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 58 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 59 GERMANY: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 60 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing government funding and favorable insurance system to drive growth
    • TABLE 61 FRANCE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 62 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 63 FRANCE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 64 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 REST OF EUROPE
    • TABLE 65 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 66 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 67 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 68 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • TABLE 69 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 11.4.2 CHINA
      • 11.4.2.1 Rising geriatric population to drive demand for AI in pathology products
    • TABLE 74 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 75 CHINA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 76 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 77 CHINA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 78 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 JAPAN
      • 11.4.3.1 Advanced healthcare infrastructure to support market growth
    • TABLE 79 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 80 JAPAN: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 81 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 82 JAPAN: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 83 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 84 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 85 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 86 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 87 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5 LATIN AMERICA
    • TABLE 88 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 89 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 90 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST & AFRICA
    • TABLE 92 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021-2028 (USD MILLION)
    • TABLE 93 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021-2028 (USD MILLION)
    • TABLE 94 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 95 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
    • FIGURE 30 KEY DEVELOPMENTS UNDERTAKEN BY MAJOR PLAYERS BETWEEN JANUARY 2020 AND MAY 2023
  • 12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022
    • FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS
  • 12.4 MARKET RANKING ANALYSIS
    • FIGURE 32 AI IN PATHOLOGY MARKET RANKING ANALYSIS OF KEY PLAYERS (2022)
  • 12.5 COMPETITIVE BENCHMARKING
    • TABLE 96 FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 97 PRODUCT FOOTPRINT ANALYSIS (25 COMPANIES)
    • TABLE 98 APPLICATION FOOTPRINT ANALYSIS (25 COMPANIES)
    • TABLE 99 REGIONAL FOOTPRINT ANALYSIS (25 COMPANIES)
  • 12.6 COMPANY EVALUATION MATRIX
    • 12.6.1 STARS
    • 12.6.2 PERVASIVE PLAYERS
    • 12.6.3 EMERGING LEADERS
    • 12.6.4 PARTICIPANTS
    • FIGURE 33 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX, 2022
  • 12.7 COMPANY EVALUATION MATRIX FOR START-UP/SME PLAYERS
    • 12.7.1 PROGRESSIVE COMPANIES
    • 12.7.2 DYNAMIC COMPANIES
    • 12.7.3 STARTING BLOCKS
    • 12.7.4 RESPONSIVE COMPANIES
    • FIGURE 34 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX FOR START-UP/SME PLAYERS, 2022
  • 12.8 COMPETITIVE SCENARIO AND TRENDS
    • 12.8.1 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 100 AI IN PATHOLOGY MARKET: PRODUCT LAUNCHES AND APPROVALS, 2020-2023
    • 12.8.2 DEALS
    • TABLE 101 AI IN PATHOLOGY MARKET: DEALS, 2020-2023
    • 12.8.3 OTHER DEVELOPMENTS
    • TABLE 102 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2020-2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • TABLE 103 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
    • FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 104 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 13.1.3 HOLOGIC, INC.
    • TABLE 105 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 37 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.4 AKOYA BIOSCIENCES, INC.
    • TABLE 106 AKOYA BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • FIGURE 38 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • TABLE 107 AIFORIA TECHNOLOGIES PLC: BUSINESS OVERVIEW
    • FIGURE 39 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2022)
    • 13.1.6 INDICA LABS INC.
    • TABLE 108 INDICA LABS INC.: BUSINESS OVERVIEW
    • 13.1.7 OPTRASCAN, INC.
    • TABLE 109 OPTRASCAN, INC.: BUSINESS OVERVIEW
    • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • TABLE 110 IBEX MEDICAL ANALYTICS LTD.: BUSINESS OVERVIEW
    • 13.1.9 MINDPEAK GMBH
    • TABLE 111 MINDPEAK GMBH: BUSINESS OVERVIEW
    • 13.1.10 TRIBUN HEALTH
    • TABLE 112 TRIBUN HEALTH: BUSINESS OVERVIEW
    • 13.1.11 TECHCYTE, INC.
    • TABLE 113 TECHCYTE, INC.: BUSINESS OVERVIEW
    • 13.1.12 DEEP BIO INC.
    • TABLE 114 DEEP BIO INC.: BUSINESS OVERVIEW
    • 13.1.13 LUMEA INC.
    • TABLE 115 LUMEA INC.: BUSINESS OVERVIEW
    • 13.1.14 VISIOPHARM
    • TABLE 116 VISIOPHARM: BUSINESS OVERVIEW
    • 13.1.15 AETHER AI
    • TABLE 117 AETHER AI: BUSINESS OVERVIEW
    • 13.1.16 AIOSYN
    • TABLE 118 AIOSYN: BUSINESS OVERVIEW
    • 13.1.17 PAIGE AI, INC.
    • TABLE 119 PAIGE AI, INC.: BUSINESS OVERVIEW
    • 13.1.18 PROSCIA, INC.
    • TABLE 120 PROSCIA, INC.: BUSINESS OVERVIEW
    • 13.1.19 PATHAI, INC.
    • TABLE 121 PATHAI, INC.: BUSINESS OVERVIEW
    • 13.1.20 TEMPUS LABS, INC.
    • TABLE 122 TEMPUS LABS, INC.: BUSINESS OVERVIEW
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
    • 13.2.2 DOMORE DIAGNOSTICS AS
    • 13.2.3 VERILY LIFE SCIENCES, LLC
    • 13.2.4 DEEPPATH
    • 13.2.5 4D PATH INC.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS